An immunoradiometric assay, that uses a monoclonal antibody attached to a solid support and developed for the detection of the ovarian tumour antigen, CA125, in serum, has been evaluated. The method was simple to perform, with reagents having a shelf-life of approximately 4 weeks. The potentials and limitations of this test are discussed.
References
1.
KatzMESchwartzPEKappDSEpithelial carcinoma of the ovary: current strategies. Ann Intern Med.1981; 95: 98–111.
NeijtJPvan der BurgMELvan LindertACMRandomised trial comparing two combination chemotherapy regimens (HEXA-CAFvsCHAP-5) in advanced ovarian carcinoma. Lancet.1984; 2: 594–600.
4.
BagshaweKDWassMSearleF. Ovarian cancer serum markers. In: NewmanCEFordCHJordanJA, eds. Advances in the Biosciences. Oxford: Pergamon, 1979; 57–66.
5.
HaijeWC. Biochemical markers in ovarian cancer: possibilities and limitations. Ann Clin BioChem.1982; 19: 258–62.
6.
MeerwaldtJHHaijeWCCooperEHBiochemical aids in the monitoring of patients with ovarian cancer. Gyn Oncol1983; 16: 209–18.
7.
FishRGGillTSAdamsMSerum haptoglobin and α1-acid glycoprotein as indicators of the effectiveness of cis-diamminedichloroplatinum (CDDP) in ovarian cancer patients—a preliminary report. Eur J Cancer Clin Oncol1984; 20: 625–30.
8.
NouwenEJPolletDESchlestracteJBHuman placental alkaline phosphatase in benign and malignant ovarian neoplasia. Cancer Res.1985; 45: 892–902.
9.
ImamurNTakahashiTLloydKLAnalysis of human ovarian tumour antigens using heterologous antisera. Detection of new antigenic systems. Int J Cancer1978; 21: 570–7.
10.
BastRCFeeneyMLazarusHReactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest1981; 68: 1331–7.
11.
BhattacharyaMChatterjeeSKBarlowJJMonoclonal antibodies recognizing tumour-associated antigen in human ovarian mucinous cystadenocarcinoma. Cancer Res.1982; 42: 1650–4.
12.
BastRCKlugTLSt JohnEA radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New Eng J Med.1983; 309: 883–7.
13.
MasuhoYZalutskyMKnappRCInteraction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Cancer Res.1984; 44: 2813–9.
14.
CanneyPAMooreMWilkinsonPMOvarian cancer antigen CA125: A prospective clinical assessment of its role as a tumour marker. Br J Cancer1984; 50: 765–9.
15.
KabawatSABastRCWelchWRImmunopathic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumours of serous, endometrioid and clear cell types. Am J Clin Path1983; 79: 98.
16.
RuibalAEncaboGMartinez-MirallesECA125 serum levels in non malignant pathologies. Bull Cancer (Paris)1984; 71: 145–6.
17.
PiccartMGoldhirschADavisBA prospective study of the correlation between CA125 serum levels and surgically verified tumour burden in ovarian cancer patients. Proceedings of AACR1985; 26: 148.
18.
RovelliLVassenaLPccorelliSMonitoring CA125 levels to predict treatment outcome in ovarian cancer patients. Proceedings of AACR1985; 26: 146.
19.
CanneyPAWilkinsonPMJamesRDCA19–9 as a marker for ovarian cancer: Alone and in comparison with CA125. Br J Cancer1985; 52: 131–3.
20.
HogbergTHammarstromSHedinACA125, CA50 and carcinoembryonic antigen (CEA) in monitoring of seropapillar/anaplastic ovarian cancer. Proceedings of ECCO1985; Stockholm 16–20 June: 135.
